All Trials

Phase II Trial of Zanzalintinib (XL-092) in Combination With Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable, systemic therapy–naïve HCC (ECOG 0–1, Child-Pugh A) receive triplet therapy with zanzalintinib (XL-092; oral multikinase TKI targeting VEGFR2/MET/TAM), durvalumab (PD-L1 inhibitor) every 4 weeks, and a single priming dose of tremelimumab (CTLA-4 inhibitor), with cohorts exploring sequencing (TKI lead-in vs immediate I/O). Excludes prior PD-1/PD-L1/CTLA-4 or MET/VEGFR TKIs, significant autoimmune disease, active viral hepatitis/HIV, and high bleeding risk; mandatory baseline tumor tissue required.

ClinicalTrials.gov ID: NCT06698250

Phase II Basket Trial of Ligufalimab (AK117) and Cadonilimab (AK104) in Advanced Hepatobiliary Cancers

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable/metastatic hepatocellular carcinoma (Child-Pugh A/B7; non-fibrolamellar) or biliary tract cancers, all progressed on prior anti–PD-1/PD-L1 therapy and ECOG 0–1, receive intravenous ligufalimab (anti‑CD47 macrophage‑activating mAb) plus cadonilimab (bispecific anti‑PD‑1/CTLA‑4 checkpoint inhibitor) every 21 days until progression/toxicity. Excludes prior liver transplant, active autoimmune disease requiring systemic therapy, uncontrolled infection, and active CNS disease; HBV/HCV-associated HCC allowed with antiviral management.

ClinicalTrials.gov ID: NCT06789848

A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable/locally advanced or metastatic HCC who are systemic therapy–naïve (non-fibrolamellar/sarcomatoid/mixed histologies) are randomized to toripalimab (PD‑1 inhibitor) plus bevacizumab with or without casdozokitug, a first‑in‑class anti–IL‑27 monoclonal antibody (p28 subunit) intended to reverse IL‑27–mediated immunosuppression and enhance T/NK cell activity. Excludes patients with significant ascites or uncontrolled effusions; compares two casdozokitug dose levels versus toripalimab/bevacizumab alone.

ClinicalTrials.gov ID: NCT06679985

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced, non-curable HCC and Child-Pugh B7 cirrhosis after 1–2 prior systemic therapies (ECOG 0–1) are randomized 2:1 to oral namodenoson 25 mg BID versus placebo. Namodenoson is a selective adenosine A3 receptor agonist targeting tumor/inflamed liver A3AR with downstream PI3K/AKT, NF-κB, and Wnt/β-catenin modulation; prior phase II suggested a survival signal in CP-B7 with favorable tolerability.

ClinicalTrials.gov ID: NCT05201404

A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated, HER2-positive (IHC 3+ or 2+/ISH+) unresectable locally advanced or metastatic gastric/GEJ adenocarcinoma receive trastuzumab plus XELOX with or without pembrolizumab, randomized to add HLX22, a humanized IgG1 anti‑HER2 antibody targeting a domain IV epitope distinct from trastuzumab. Designed to test whether dual HER2 blockade with HLX22 improves PFS/OS versus trastuzumab+XELOX (± pembrolizumab); ECOG 0–1 required, no prior HER2 therapy.

ClinicalTrials.gov ID: NCT06532006

A Phase II Trial of Avutometinib in Combination With Defactinib in Metastatic Diffuse Gastric Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable/metastatic diffuse-type gastric or GEJ cancer (including poorly cohesive/signet ring or CDH1/RHOA-mutant tumors) after at least one prior platinum/fluoropyrimidine regimen, ECOG 0–1, and tumor amenable to fresh biopsy. Treatment is oral avutometinib (dual RAF/MEK “clamp”) plus defactinib (FAK/PYK2 inhibitor) on a 3-weeks-on/1-week-off schedule; prior MEK/RAF/FAK inhibitor exposure excluded.

ClinicalTrials.gov ID: NCT06487221

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable, advanced/metastatic gastric or GEJ adenocarcinoma that is CLDN18.2-positive after at least one prior fluoropyrimidine/platinum regimen (ECOG 0–1; HER2-negative) are randomized to AZD0901 (sonesitatug vedotin), a CLDN18.2-targeted MMAE antibody–drug conjugate, versus investigator’s choice of standard therapies (e.g., ramucirumab/paclitaxel, paclitaxel, docetaxel, irinotecan, TAS-102, or apatinib). Trial excludes prior MMAE ADCs or non-antibody CLDN18.2 therapies and recent significant bleeding/CNS disease.

ClinicalTrials.gov ID: NCT06346392

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic/advanced clear cell RCC who progressed after at least one systemic line including a PD-1/PD-L1 inhibitor (two cohorts based on prior VEGF/HIF-2α exposure) receive ivonescimab monotherapy IV q3w. Ivonescimab is a bispecific PD-1/VEGF antibody designed to simultaneously restore antitumor immunity and inhibit angiogenesis.

ClinicalTrials.gov ID: NCT06940518

EXACT: Randomized Phase II Trial of XL092 in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced/metastatic clear cell RCC who progressed on or after adjuvant anti–PD-1/PD-L1 therapy (no prior systemic therapy otherwise) are randomized to zanzalintinib (XL092), an oral multi-targeted TKI of VEGFR2/MET/TAM kinases, versus XL092 plus nivolumab (PD-1 inhibitor). Key exclusions include untreated/unstable CNS mets and active autoimmune disease requiring immunosuppression.

ClinicalTrials.gov ID: NCT06863311

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent or metastatic cervical squamous/adenocarcinoma after exactly one prior platinum doublet (±bevacizumab) and prior PD-1/PD-L1 therapy, ECOG 0–1, and measurable disease are randomized to sacituzumab tirumotecan (TROP2-directed ADC with topoisomerase I payload) versus physician’s choice of single-agent chemotherapy (pemetrexed, tisotumab vedotin, topotecan, vinorelbine, gemcitabine, or irinotecan). Primary efficacy focuses on overall survival in TROP2-high and all-comer populations.

ClinicalTrials.gov ID: NCT06459180